期刊
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
卷 24, 期 8, 页码 1229-1235出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1386207323666200902135349
关键词
Gastric cancer; predictive factor; prognostic factor; Osteopontin; biomarker; oncologist
资金
- Ankara University Medical Foundation
The study indicates that higher serum OPN levels are associated with shorter survival time in patients with advanced gastric cancer. Patients who respond to DCF treatment have lower plasma OPN levels, with performance status and plasma OPN levels being significant factors in overall survival.
Objective: Osteopontin (OPN), a phosphorylated sialoprotein, has been shown to overex-press in a variety of cancers and to contribute tumor progression and metastasis by increasing cell migration and adhesion. In the current study, we aimed to investigate the prognostic and predictive role of OPN in patients with advanced gastric cancer. Methods: A total of 42 consecutive chemonaive patients with advanced gastric cancer and 29 healthy controls were included. The patients were treated with a modified DCF regimen. The blood samples were obtained before each chemotherapy cycle from the patients and once from healthy controls. The plasma OPN is measured by ELISA. Results: The overall response and disease stabilization rates were 25% and 72%, respectively. The median serum OPN level of the patient group was significantly higher compared to healthy con-trols (176.9 ng/ml (range: 41.5-521.4) vs 64.3 ng/ml (range 42.1-105.3 ng/ml), p < 0.0001). The me-dian overall survival time was 7.0 +/- 1.1 (95% CI: 4.9-9.2) months and 1-year overall survival rate was 20.8%. The patients who responded to mDCF had lower plasma OPN levels than the non-re-sponding ones (110.7 +/- 29.3 ng/mL, 211.9 +/- 24.4 ng/mL respectively, p=0.002). The performance sta-tus and the plasma OPN levels were found to be significant factors for overall survival in the multi-variate analysis (p=0.004 and 0.016, respectively). Conclusion: The serum OPN seems to be a novel significant prognostic and predictive factor in pa-tients with advanced gastric cancer who were treated with DCF regimen.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据